Przegląd Dermatologiczny

Pełna treść

1/2026 vol. 113
Opis przypadku

Papillary Thyroid Carcinoma in a Patient with Psoriasis Treated with Secukinumab

Munise Daye 1
,
Hilmi Uygun 1

  1. Department of Dermatology, Faculty of Medicine, Necmettin Erbakan University, Turkey

DOI: https://doi.org/10.5114/dr.2026.161419
Data publikacji online: 2026/06/05
Plik artykułu
Papillary Thyroid Carcinoma .pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Myers W.A., Gottlieb A.B., Mease P.: Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006, 24, 438-447.
  2. Kiltz U., Sfikakis P.P., Gaffney K., Sator P.G., von Kiedrowski R., Bounas A., et al.: Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in europe: baseline data from SERENA study. Adv Ther 2020, 37, 2865-2883.
  3. Bruni M., Lobefaro F., Pellegrini C., Mastrangelo M., Gualdi G., Esposito M., et al.: Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment. Expert Opin Biol Ther 2025, 25, 395-411.
  4. Vaengebjerg S., Skov L., Egeberg A., Loft N.D.: Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol 2020, 156, 421-429.
  5. Trafford A.M., Parisi R., Kontopantelis E., Griffiths C.E., Ashcroft D.M.: Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol 2019, 155, 1390-1403.
  6. Lee J.H., Kim H.J., Han K.D., Kim H.N., Park Y.M., Lee J.Y., et al.: Cancer risk in 892 089 patients with psoriasis in Korea: a nationwide population-based cohort study. J Dermatol 2019, 46, 95-102.
  7. Lee J.W., Jung K.J., Kim T.G., Lee M., Oh J., Jee S.H., et al.: Risk of malignancy in patients with psoriasis: a 15-year nationwide population-based prospective cohort study in Korea. J Eur Acad Dermatol Venereol 2019, 33, 2296-2304.
  8. Boffetta P., Gridley G., Lindelöf B.: Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Investig Dermatol 2001, 117, 1531-1537.
  9. Kim S.Y., Yoo D.M., Chung J., Choi H.G.: Thyroid cancer and psoriasis: a nested case–control study. Diagnostics 2022, 12, 2297.
  10. Rendon A., Schäkel K.: Psoriasis pathogenesis and treatment. Int J Mol Sci 2019, 20, 1475.
  11. West J., Ogston S., Foerster J.: Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS One 2016, 11, e0153740.
  12. Hong J.Y., Ahn J., Won S., Kim S.M., Cho Y.A., Kim C.Y., et al.: Risk of malignancy in patients with psoriasis according to treatment modalities in Korea: a nationwide cohort study. Sci Rep 2022, 12, 20690.
  13. Fiorentino D., Ho V., Lebwohl M.G., Leite L., Hopkins L., Galindo C., et al.: Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 2017, 77, 845-854.
  14. Zou W., Restifo N.P.: T(H)17 cells in tumour immunity and immunotherapy [published correction appears in Nat Rev Immunol 2011, 11, 565]. Nat Rev Immunol 2010, 10, 248-256.
  15. Vitiello G.A., Miller G.: Targeting the interleukin-17 immune axis for cancer immunotherapy. J Exp Med 2019, 217, e20190456.
  16. Lebwohl M., Deodhar A., Griffiths C.E.M., Menter M.A., Poddubnyy D., Bao W., et al.: The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 2021, 185, 935-944.
  17. Reich K., Warren R.B., Coates L.C., Di Comite G.: Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol 2020, 34, 1161-1173.
  18. Nast A., Smith C., Spuls P.I., Avila Valle G., Bata-Csörgö Z., Boonen H., et al.: EuroGuiDerm Guideline on the systemic treat­ment of psoriasis vulgaris–Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021, 35, 281-317.
  19. Kivitz A.J., Nash P., Tahir H., Everding A., Mann H., Kaszuba A., et al.: Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 Study. Rheumatol Ther 2019, 6, 393-407.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Indeks osobowy
Udostępnij
without publication fees
without publication fees
Dostępne w
Zintergrowane z
plagiat pl
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications